Recent Advances in Treating Endometrial and Cervical Cancers - Episode 10

Future Directions in the Treatment of Advanced or Recurrent Endometrial Cancer

December 20, 2023

Bradley Monk, MD, Dana M. Chase, MD, FACOG, David O'Malley, MD, Leslie M. Randall, MD, Thomas C. Krivak, MD

Experts are enthusiastic about the potential of antibody drug conjugates to de-escalate therapy and reduce toxicity in advanced and recurrent endometrial cancer treatment, with a focus on the importance of diversity plans in clinical trials to ensure broader applicability.

EP. 1: Diagnosing and Staging Patients With Endometrial Cancer

EP. 2: Updated NCCN Guidelines for the Treatment of Advanced or Recurrent Endometrial Cancer

EP. 3: Shared Decision-Making in Advanced or Recurrent Endometrial Cancer

EP. 4: The Role of dMMR in the Progression of Endometrial Cancer

EP. 5: Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Cancer: Data from the RUBY Trial

EP. 6: The NRG-GY018 Trial: Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer

EP. 7: Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer

EP. 8: Advances in Anti-HER2 ADCs in Patients With Advanced or Recurrent Endometrial Cancer

EP. 9: Recent Data on Anti-TROP2 ADCs for Patients With Advanced or Recurrent Endometrial Cancer

Now Viewing

EP. 10: Future Directions in the Treatment of Advanced or Recurrent Endometrial Cancer

EP. 11: Staging and Biomarker Testing For Patients With Cervical Cancer